-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ERAS-601 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ERAS-601 in Solid Tumor Drug Details: ERAS-601 is under development for...
-
Product Insights
NewNet Present Value Model: Erasca Inc’s ERAS-007
Empower your strategies with our Net Present Value Model: Erasca Inc's ERAS-007 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ERAS-601 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ERAS-601 in Pancreatic Cancer Drug Details: ERAS-601 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ERAS-601 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ERAS-601 in Gastric Cancer Drug Details: ERAS-601 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ERAS-601 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ERAS-601 in Non-Small Cell Lung Cancer Drug Details: ERAS-601 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BGB-15025 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BGB-15025 in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BGB-15025 in Esophageal Cancer Drug Details: BGB-15025 is under development for...
-
Thematic Analysis
NewArtificial Intelligence – Executive Briefing (Third Edition) – Thematic Intelligence
Reasons to buy the ‘Artificial Intelligence’ thematic intelligence report: This report provides an overview of generative AI, placing it in the context of the broader AI theme. It provides market forecasts and analysis of data signals, including polls, patent filings, venture financing, social media mentions, and hiring. The report examines the competitive landscape development with new products and deals. The report helps understand the geopolitical impact on AI’s supply chain​. It focuses on generative AI and the threats and opportunities...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBP-1008 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBP-1008 in Triple-Negative Breast Cancer (TNBC) Drug Details: CBP-1008...
-
Product Insights
NewNet Present Value Model: Erasca Inc’s ERAS-601
Empower your strategies with our Net Present Value Model: Erasca Inc's ERAS-601 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.